Allogene, Overland woo an experienced hand from WuXi to steer their allogeneic CAR-T JV
Allogene Overland Biopharm, the joint venture David Chang and Ed Zhang set up to turbocharge the development of off-the-shelf CAR-T therapies in China, has locked in its first CEO.
Shuyuan Yao joins from WuXi Advanced Therapies, the cell and gene therapy-focused arm of the sprawling contract testing, development and manufacturing group. Most recently CSO, head of research and technology development, Yao was credited for driving the creation of WuXi’s cell therapy R&D business unit, and had led everything from tech acquisition and development to translation and application.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.